Message #71 From:
NewsBot Date: March 26, 2007 06:30:00 AM
EFSF News eFoodSafety.com, Inc. Formulates All-Natural Cold Remedy
SCOTTSDALE, Ariz.--(BUSINESS WIRE)--eFoodSafety.com, Inc. (OTCBB: EFSF), a Company dedicated to improving health conditions around the world through innovative products and technologies, today announced that it has formulated a novel all-natural cold remedy in the form of a chewable lozenge featuring Citroxin O2. Citroxin O2 is an all-food grade formula, containing no chemicals or pharmaceuticals. It has been proven one hundred percent effective in vitro by independent laboratory testing against many pathogens, including: Staph Aureus, Streptococcus Pneumoniae, and Pseudomonas Aeruginosa. Citroxin O2 has proven anti-viral capability, a vital necessity as 200 different known viruses can cause the common cold.
This Citroxin O2 formula will contain Zinc, several vital electrolytes, vitamin C and immune enhancing probiotics. As a lozenge, the unique benefits of Citroxin O2 and synergistic ingredients will begin working immediately in the membranes of the sinuses and oral cavity to help reduce both the severity and duration of the cold virus.
The common cold with its nagging and oftentimes severe symptoms is pervasive in society. Every year, the U.S. population experiences up to one billion colds. Although colds can happen anytime, they occur most often in the winter and spring. Annually, approximately 189 million school days are lost to colds with another 126 million days of work lost for at least one parent to stay home to tend to their sick child. Up to the age of 17, the number of colds caught per year is 5-12. People above the age of 18 catch 2-4 colds per year.
The economic impact of the common cold is staggering. Studies have shown that in the U.S. on a yearly basis, $2.9 billion is spent on OTC cold remedies, $400 million on prescriptions, and another $1.1 billion on anti-biotic prescriptions to treat secondary bacterial infections due to colds. Approximately 100 million visits are paid to the doctor each year from contracting a cold, resulting in a cost of about $7.7 billion. All told, it is estimated that the annual cost to the U.S. economy from the common cold equals about $40 billion each year.
Patricia Gruden, President and CEO of eFoodSafety.com, Inc. stated, “We’re pleased to introduce this new product to our expanding and evolving list of better health related offerings. We anticipate commencing clinical trials on this product within the next 60 days.”
Gruden further commented, “It’s an exciting time here at eFoodsafety.com as evidenced by many of our announcements of recent months. Having now established a strong distribution channel for Cinnergen™ including some of the top retailers in the world, we believe the potential for cross-selling opportunities is high. We have established a strong foundation allowing us to leverage future growth and we are now seeing tangible results in the form of increasing sales. We anticipate reporting the increasing revenues in forthcoming quarters having already experienced the typical 60-90 day lag time from initial sale to collection of the receivable allowing us to physically book the revenues.”
eFoodSafety.com, Inc. is dedicated to improving health conditions around the world through its innovative technologies. The company’s Knock-Out Technologies, Ltd. subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal product, Citroxin (formerly named Big Six Plus) – EPA Reg. No. 82723-1 that kills six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, Avian Influenza, and Black Mold. The sporicidal product has completed its final efficacy laboratory study requisite for EPA registration. In the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis with 100% efficacy on both hard and porous surfaces. The company’s MedElite, Inc. subsidiary distributes clinically proven products to physicians who then prescribe the products for their patients. It recently became the owner of the Talsyn™-CI/bid Scar Cream, that has been clinically proven to facilitate and improve the appearance, redness and strength of scars (www.talsyn.com), as well as seven (7) other products in the Talsyn™ line. The Company is also owner of Cinnergen™, a clinically-studied, non-prescription liquid whole food nutritional supplement that promotes healthy glucose metabolism (www.cinnergen.com) and Cinnechol™, a new multi-faceted nutritional supplement specifically designed to naturally reduce total cholesterol levels without causing any side effects. The Company has entered into a joint venture agreement with CK41 Direct, Inc. to launch the PurEffect™ anti-acne skin care system.
Statements contained in this release that are not strictly historical are “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.. The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Editors and investors are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company’s actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company’s products and services, our ability to continue to develop markets, general economic conditions, our ability to secure additional financing for the Company and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.
